JOHN KIRKWOOD to MART-1 Antigen
This is a "connection" page, showing publications JOHN KIRKWOOD has written about MART-1 Antigen.
Connection Strength
0.231
-
Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012 May; 35(4):359-66.
Score: 0.101
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
Score: 0.060
-
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
Score: 0.045
-
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004 Mar; 50(3):564-73.
Score: 0.014
-
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A. 2000 Jan 04; 97(1):400-5.
Score: 0.011